AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39375952
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing
Trial: 33212267
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with low-power laser, 660 nm, 40 mW, 120 J/cm2, 4.8 J, 120 s per point and methylene blue (0.005 %) as photosensitizer
Trial: 33212267
Drug: Topical Acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Acyclovir (AC) 5%
Trial: 33421649
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of HPV vaccine (Cervarix or Gardasil-9)
Trial: 33421649
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV vaccine (Cervarix or Gardasil-9) given 6 months apart
Trial: 33421649
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of HPV vaccine (Cervarix or Gardasil-9)
Trial: 32187166
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOACs), primarily Rivaroxaban and Apixaban
Trial: 32187166
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not specified (standard treatment with warfarin)
Trial: 36242636
Drug: 5-ALA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ALA (20 mg/kg) administered orally or via a gastric tube prior to surgery
Trial: 34182577
Drug: Parent-administered oral
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered oral stimulation (PIOMI)
Trial: 34182577
Drug: Professional-administered oral
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional-administered oral stimulation (PIOMI)
Trial: 33903280
Drug: High-dose intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intervention
Trial: 33903280
Drug: Low-dose intervention
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intervention
Trial: 32202965
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal treatment (ENDO)
Trial: 33288629
Drug: Fixed-dose darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed-dose darbepoetin (0.45 µg/kg every 4 weeks)
Trial: 33288629
Drug: Titration-dose darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration-dose darbepoetin (based on hemoglobin levels)
Trial: 35175572
Drug: Cimetidine as
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine as adjuvant therapy
Trial: 35175572
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without cimetidine
Trial: 33138061
Drug: 30 g/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/120 kcal whey-protein drink
Trial: 33138061
Drug: 70 g/280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 g/280 kcal whey-protein drink
Trial: 32676977
Drug: TRV250 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV250 (subcutaneous administration)
Trial: 32676977
Drug: TRV250 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV250 (oral administration)
Trial: 33589450
Drug: TKI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI plus local consolidative radiation therapy (LCRT)
Trial: 37552354
Drug: 6-month adjuvant
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month adjuvant chemotherapy with S-1
Trial: 37552354
Drug: 12-month adjuvant
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month adjuvant chemotherapy with S-1
Trial: 37552354
Drug: 6-month adjuvant
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month adjuvant chemotherapy with S-1 (in patients who completed the regimen)
Trial: 37552354
Drug: 12-month adjuvant
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month adjuvant chemotherapy with S-1 (in patients who completed the regimen)
Trial: 33994406
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy targeting LDL-C <70 mg/dl
Trial: 33994406
Drug: Standard statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard statin therapy targeting LDL-C 100-120 mg/dl
Trial: 34097646
Drug: Personalized support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized support at home (monthly home-based visits focusing on nutritional counseling and pregnancy management)
Trial: 34949626
Drug: Optimised physiotherapist-led
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised physiotherapist-led treatment package including advice and education, exercise therapy, and orthotics.
Trial: 34949626
Drug: Condition-specific advice,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condition-specific advice, health-promotion advice, exercise types, exercise into 'acceptable' levels of pain, exercise dosage, and type of orthoses.
Trial: 34949626
Drug: Electrotherapy, acupuncture,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrotherapy, acupuncture, and manual therapy were excluded from the treatment options.
Trial: 35765796
Drug: Phyto corrective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyto corrective mask (once weekly), phyto corrective gel (twice daily), resveratrol antioxidant serum (at night)
Trial: 35165099
Drug: Combination (Lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (Lapatinib and Trastuzumab)
Trial: 34051120
Drug: Home Biofeedback
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home Biofeedback Therapy (HBT)
Trial: 34051120
Drug: Office Biofeedback
RxNorm normalized name: Office First Aid Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office Biofeedback Therapy (OBT)
Trial: 35311720
Drug: Bobath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bobath therapy with additional specific soft tissue mobilizations
Trial: 33553040
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g of traditional fermented food (Ash-Kardeh) daily in addition to the usual treatment
Trial: 33553040
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment of diabetic patients
Trial: 32967500
Drug: ATP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP group (androl, thalidomide, and PND capsule)
Trial: 35483677
Drug: Buprenorphine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 2.5 μg/kg
Trial: 35438672
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g potato protein
Trial: 35438672
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g milk protein
Trial: 33653909
Drug: Conventional Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Oxygen Therapy via T-tube
Trial: 34628372
Drug: Patient-Controlled Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Intravenous Analgesia (IVPCA)
Trial: 32823218
Drug: Single parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single parenteral dose of 300,000 IU of vitamin D
Trial: 32379661
Drug: Integrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative therapy (short-term psychodynamic psychotherapy & cognitive-behavioral therapy)
Trial: 33795561
Drug: Abrocitinib 30
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abrocitinib 30 mg
Trial: 33795561
Drug: Abrocitinib 10
RxNorm normalized name: abrocitinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrocitinib 10 mg
Trial: 36207050
Drug: 1.5×10^6 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5×10^6 IU of low-dose IL-2
Trial: 35713352
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy (DT) sessions using the Empathic Communication Coding System (ECCS-DT)
Trial: 33130645
Drug: Proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed treatment protocol including drugs affecting pathogenetic mechanisms of the disease.
Trial: 33130645
Drug: Proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed treatment protocol
Trial: 34532749
Drug: Guanxin Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanxin Danshen Dropping Pill (0.4 g, thrice daily) and Andrographis tablet (0.2 g, thrice daily) for 4 weeks
Trial: 34532749
Drug: Guanxin Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanxin Danshen Dropping Pill (0.4 g, thrice daily)
Trial: 32196856
Drug: Intramuscular hyosine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hyosine n-butyl bromide (HBB) 40 mg (2 mL)
Trial: 32196856
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL of water for injection)
Trial: 33522342
Drug: Pravastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (2 × 20 mg p.o) in addition to aspirin (80 mg p.o) and calcium (1 g p.o) from 14 to 20 weeks until delivery
Trial: 33825498
Drug: Conventional-dose CT
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CT (CDCT) (n = 1539 patients)
Trial: 36004716
Drug: Probiotic Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Bacillus clausii UBBC‐07 (2×10^9 per 5 ml vial) taken daily twice for three months
Trial: 33563473
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration during KT
Trial: 34610332
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy in combination with surgery
Trial: 32602373
Drug: Small needle-knife
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small needle-knife therapy (1 to 3 treatments over seven days)
Trial: 32602373
Drug: Oral Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Celecoxib
Trial: 32870471
Drug: Once-weekly dulaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly dulaglutide 0.75 mg
Trial: 33599688
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with carboplatin
Trial: 33599688
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy without carboplatin
Trial: 33675133
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (poor prognostic pathologic factors; concurrent 56-Gy chemoradiotherapy with weekly cisplatin)
Trial: 32214062
Drug: Task-based mirror
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-based mirror therapy (TBMT) for 25 minutes per day for 25 days
Trial: 32214062
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (control group) for 25 minutes per day for 25 days
Trial: 37477875
Drug: ChAd155-RSV high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd155-RSV high dose (5 × 10^10 viral particles)
Trial: 36179066
Drug: UP165 (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP165 (corn leaf extract) 250 mg/day
Trial: 36179066
Drug: UP165 (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP165 (corn leaf extract) 500 mg/day
Trial: 35301135
Drug: Electronic sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic sleep positional therapy wearable device
Trial: 35522187
Drug: Microfluidic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfluidic sperm preparation
Trial: 32817311
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 400 μg oral supplementation once daily for a year
Trial: 32683215
Drug: Hand Arm
RxNorm normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 g TOPICAL LIQUID [Hand Armor]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand Arm Bimanual Intensive Therapy (HABIT)
Trial: 32964537
Drug: Diuretic responsiveness
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic responsiveness
Trial: 36209072
Drug: 1.0% phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% phentolamine mesylate ophthalmic solution (PMOS)
Trial: 34290573
Drug: Bioresorbable vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioresorbable vascular scaffold (BVS) + optimal medical therapy (OMT)
Trial: 34863458
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus carboplatin chemotherapy
Trial: 33612630
Drug: Caromma biscuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caromma biscuit (100 g/day for 4 weeks)
Trial: 33612630
Drug: Temma biscuit
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temma biscuit (100 g/day for 4 weeks)
Trial: 32966845
Drug: Radiotherapy dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy dose
Trial: 34195469
Drug: Socio-spiritual intervention
RxNorm normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Socio-spiritual intervention consisting of four weekly face-to-face sessions focusing on spirituality, social support, and information needs
Trial: 33534750
Drug: Radio frequency‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radio frequency‐induced heat therapy (RFHT)
Trial: 32135414
Drug: Chumlea's formulas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chumlea's formulas for whites (CC)
Trial: 33378079
Drug: Implants without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants without peri-implantitis
Trial: 33378079
Drug: Implants diagnosed
RxNorm normalized name: AUTOLOGOUS CD34+ CELLS ISOLATED FROM BONE MARROW OF NEWLY DIAGNOSED X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (X-SCID) PATIENTS, TRANSDUCED EX VIVO WITH A SELF-INACTIVATING LENTIVIRAL VECTOR, ENCODING CODON-OPTIMIZED HUMAN INTERLEUKIN-2 RECEPTOR SUBUNIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants diagnosed with peri-implantitis
Trial: 33378079
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors for buccal PISTD
Trial: 32957034
Drug: Single-dose patellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose patellar tendon isometric exercise protocol
Trial: 33385511
Drug: Ziziphus spinosa
RxNorm normalized name: Ziziphus jujuba var. spinosa seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziziphus spinosa (ZS) 2 g daily
Trial: 32462542
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (1 µg/kg during a 10-min infusion)
Trial: 32462542
Drug: Subcutaneous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dexmedetomidine (1 µg/kg during a 10-min infusion)
Trial: 33964223
Drug: R21 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R21 plus 25 μg MM (Group 1)
Trial: 33964223
Drug: R21 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R21 plus 50 μg MM (Group 2)
Trial: 33544883
Drug: Tildrakizumab 200
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab 200 mg (after switching from ETN)
Trial: 35975564
Drug: Ginseng (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (1 g/day)
Trial: 33819509
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus rhamnosus GG administered for 3 months
Trial: 32120316
Drug: Synbiotic supplementation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplementation (two synbiotic capsules daily for 2 months)
Trial: 35484817
Drug: Twice-daily enoxaparin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily enoxaparin
Trial: 33818939
Drug: Hydrophilic nutrients
RxNorm normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic nutrients (BESTFertil dietary supplement, 4 capsules per day)
Trial: 33818939
Drug: Lipophilic nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipophilic nutrients (dietary supplement 'BrudiPlus', 3 capsules per day)
Trial: 34478166
Drug: Niraparib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 1
Trial: 34478166
Drug: Niraparib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 2
Trial: 34016868
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% topical solution
Trial: 35507334
Drug: Nomacopan, 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomacopan, 90 mg subcutaneously on day 1 and 30 mg subcutaneously daily until day 42
Trial: 34626008
Drug: Low-dose rhEPO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rhEPO (40 IU/kg)
Trial: 34626008
Drug: rhEPO micro-doses
RxNorm normalized name: docusate Enema [Colace Micro-Enema]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO micro-doses (900 IU)
Trial: 34626008
Drug: Washout phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Washout phase after rhEPO administration
Trial: 36001436
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (oral and intravenous, variable and fixed doses)
Trial: 35708758
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (targeted antifungal therapy driven by culture results)
Trial: 33431819
Drug: CB1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CB1 antagonist AM281
Trial: 32530339
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine treatments only)
Trial: 35389961
Drug: High-dose Levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Levothyroxine
Trial: 35389961
Drug: High-dose Methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Methylprednisolone
Trial: 35389961
Drug: Combo (High-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combo (High-dose Levothyroxine + High-dose Methylprednisolone)
Trial: 35389961
Drug: Control (No
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (No hormonal therapy)
Trial: 35490603
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL drain removal
Trial: 35490603
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL drain removal
Trial: 35490603
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL drain removal
Trial: 34088920
Drug: Regular calcium
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular calcium + 5 x 10^8 CFU/day L. casei CRL 431 (Casei)
Trial: 35209942
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day probiotic cheese
Trial: 32713421
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy after 6 weeks
Trial: 32713421
Drug: CPAP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP titration
Trial: 34309665
Drug: Standard arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arm (bevacizumab administered on the same day as chemotherapy)